A Prospective Observational Study on the Effect of Improving Blood Lipid Management on the Clinical Prognosis of Symptomatic Intracranial Atherosclerotic Stenosis (sICASBLM)

What this Trial Is About

Researchers are evaluating how improving blood lipid management affects the clinical outcomes of patients with moderate to severe symptomatic intracranial atherosclerotic stenosis who have LDL cholesterol levels above 1.8 mmol/L and are not undergoing endovascular therapy. The study compares conventional lipid management alone to conventional lipid management combined with PCSK9 inhibitors to see if this approach can reduce recurrent strokes. Participants receive either conventional lipid management with statins (atorvastatin, rosuvastatin, or simvastatin) or the same treatment plus PCSK9 inhibitors for 6 to 12 months. The study groups include an intervention group receiving the combined treatment and a control group receiving only statins. No randomization or masking is involved, and the study is observational in design. Throughout the study, participants will be monitored for recurrent stroke occurrences between 6 and 12 months. Researchers will also assess intracranial arterial conditions, plaque changes, vascular remodeling, and any adverse events during this period. The study involves imaging with 3T magnetic resonance angiography or multi-mode MR scans, along with clinical evaluations and safety monitoring. The total participation duration is up to 12 months, with data collection focused on clinical outcomes and vascular health.

Improving Blood Lipid Management in Symptomatic Intracranial Atherosclerotic Stenosis on Clinical Outcome